Journal: Oxidative Medicine and Cellular Longevity

Article Title: The Novel Nrf2 Activator Omaveloxolone Regulates Microglia Phenotype and Ameliorates Secondary Brain Injury after Intracerebral Hemorrhage in Mice

doi: 10.1155/2022/4564471

Figure Lengend Snippet: Omav reduced the expression of inflammatory cytokines but enhanced BV2 phagocytosis under the stress of OxyHb. (a–c) Levels of the Il-1β, Tnf-α , and Il-10 mRNAs in treated BV2 cells ( n = 3). (d) Representative fluorescent images of the phagocytosis assay in BV2 cells. β -Actin in BV2 cells was labeled with phalloidin-FITC, and RBCs were labeled with DiI. Scale bar: 50 μ m. (e) Quantification of the phagocyte proportion according to fluorescence ( n = 6). (f and g) The concentrations of IL-1 β and TNF- α were detected using ELISAs ( n = 6). (h) Phagocytosis ratio of BV2 cells in each group detected via FCM. (i) Quantification of the ratio of BV2 cells phagocytoses labeled RBCs from each group ( n = 3). Data are presented as the means ± SEM. ∗ P < 0.05 and ∗∗ P < 0.01 compared with the control group; # P < 0.05 and ## P < 0.01 compared with the OxyHb group; † P < 0.05 and †† P < 0.01 compared with the OxyHb+Omav group.

Article Snippet: The levels of TNF- α (cat. no. KE10003) and IL-1 β (cat. no. KE10003) in the supernatants of treated BV2 cells were examined using ELISA kits (Proteintech) according to the manufacturer's instructions.

Techniques: Expressing, Phagocytosis Assay, Labeling, Fluorescence, Control

Journal: Oxidative Medicine and Cellular Longevity

Article Title: The Novel Nrf2 Activator Omaveloxolone Regulates Microglia Phenotype and Ameliorates Secondary Brain Injury after Intracerebral Hemorrhage in Mice

doi: 10.1155/2022/4564471

Figure Lengend Snippet: Omav reduced the expression of proinflammatory genes and proteins after ICH. (a) Immunofluorescence staining for Iba-1 (green) and iNOS (red) in the ipsilateral basal ganglia region 3 days after ICH; the nuclei were stained with DAPI (blue); scale bar: 50 μ m ( n = 6). (b) Quantification of the ratio of microglia expressing iNOS. (c–e) qRT-PCR analysis of the expression of the mRNAs encoding iNOS, IL-1 β , and TNF- α ( n = 3). (f) Western blot showing iNOS levels in peripheral hematoma tissues from each group ( n = 6). (g) Quantitative analysis of the iNOS band. (h–i) The concentrations of IL-1 β and TNF- α in perihematoma 3 days after ICH were detected using ELISAs ( n = 6). Data are presented as the means ± SEM. ∗ P < 0.05 and ∗∗ P < 0.01 compared with the control group; # P < 0.05 and ## P < 0.01 compared with the OxyHb group; † P < 0.05 and †† P < 0.01 compared with the OxyHb+Omav group.

Article Snippet: The levels of TNF- α (cat. no. KE10003) and IL-1 β (cat. no. KE10003) in the supernatants of treated BV2 cells were examined using ELISA kits (Proteintech) according to the manufacturer's instructions.

Techniques: Expressing, Immunofluorescence, Staining, Quantitative RT-PCR, Western Blot, Control

Journal: bioRxiv

Article Title: Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

doi: 10.1101/2024.12.21.629876

Figure Lengend Snippet: A: PCA analysis of 4T1-Luc2 CRISPR CTL and CRISPR STING treated or not by paclitaxel and analyzed by 3’Seq RNA Profiling. B, C: Volcano plots representing differentially up- and downregulated expressed under paclitaxel treatment in 4T1-Luc2 CRISPR CTL and CRISPR STING , respectively. D, E: Signaling pathway signatures up- or downregulated by paclitaxel in 4T1-Luc2 CRISPR CTL and CRISPR STING , respectively. F, G: Concentration in CCL5 and CXCL1 by ELISA in the culture medium of 4T1-Luc2 CRISPR CTL and CRISPR STING treated or not by paclitaxel. H: Concentration in CXCL1 by ELISA spot in the culture medium of paclitaxel-treated 4T1-Luc2 CRISPR CTL and CRISPR STING under treatment with AS602868 or not.

Article Snippet: For ELISA assays, levels of different chemokines in cell supernatants were determined according to the manufacturer’s protocols using following kits: CXCL1 (Mouse CXCL1 Sandwich ELISA Kit, Proteintech) and CCL5 (Mouse CCL5 Sandwich ELISA Kit, Proteintech).

Techniques: CRISPR, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

doi: 10.1101/2024.12.21.629876

Figure Lengend Snippet: A: Impact of STING on paclitaxel-induced transcriptional expression (3’SRP) of Cxcl1, Cxcl5, Ccl5 and Ccl20 comparing fold-change expression (paclitaxel versus untreated) in both CRISPR CTL and CRISPR STING . B: Transcriptional expression fold change of Cxcl1, Cxcl5, Ccl5 and Ccl20 in CRISPR CTL and CRISPR STING under paclitaxel or not. C : Expression of CXCL1 and CCL5 by human TNBC cells using scRNAseq analysis from Broad Institute ( https://singlecell.broadinstitute.org/single_cell/study/SCP1106/stromal-cell-diversity-associated-with-immune-evasion-in-human-triple-negative-breast-cancer ).

Article Snippet: For ELISA assays, levels of different chemokines in cell supernatants were determined according to the manufacturer’s protocols using following kits: CXCL1 (Mouse CXCL1 Sandwich ELISA Kit, Proteintech) and CCL5 (Mouse CCL5 Sandwich ELISA Kit, Proteintech).

Techniques: Expressing, CRISPR

Journal: bioRxiv

Article Title: Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

doi: 10.1101/2024.12.21.629876

Figure Lengend Snippet: A: Concentration in CXCL1 of culture medium containing 4T1-Luc2 CRISPR CTL and CRISPR CXCL1 cells treated by paclitaxel or not. B: Apoptotic cell death evaluated by flow cytometry of AnnV+/PI- cells in 4T1-Luc2 CRISPR CTL and CRISPR CXCL1 after paclitaxel treatment or not. C : Proliferative EdU+ cells evaluated by flow cytometry of AnnV+/PI- cells in 4T1-Luc2 CRISPR CTL and CRISPR CXCL1 after paclitaxel treatment or not. D : Expression of CXCL3, CXCL5, CXCL6, CXCL8 and CXCL17 (CXC ELR+ chemokines) by human TNBC cells and associated prognosis using BC-GenExMiner tool ( ; ; ).

Article Snippet: For ELISA assays, levels of different chemokines in cell supernatants were determined according to the manufacturer’s protocols using following kits: CXCL1 (Mouse CXCL1 Sandwich ELISA Kit, Proteintech) and CCL5 (Mouse CCL5 Sandwich ELISA Kit, Proteintech).

Techniques: Concentration Assay, CRISPR, Flow Cytometry, Expressing

Journal: bioRxiv

Article Title: Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

doi: 10.1101/2024.12.21.629876

Figure Lengend Snippet: A: Primary tumor growth of 4T1-Luc2 CRISPR CTL and CRISPR CXCL1 in Balb/c mice. B: Experimental in vivo protocol of Balb/c mice allografted with 4T1-Luc2 cell line and treated with paclitaxel and/or navarixin or not. C: Tumor volume measured on mice treated with paclitaxel and/or navarixin or not (d26). D: Number of lung metastases on mice treated with paclitaxel and/or navarixin or not (d40). E: Characterization (viability, CD4 and NKp46 markers) of splenocytes migrating across a transwell membrane in the culture medium containing ex vivo 4T1-Luc2 tumor slices and treated with paclitaxel and/or navarixin or not. F: Immunohistochemical count of CD8+ T cells and NCR1+ NK cells (all location and intratumor) in tumors treated by paclitaxel and/or navarixin or not. G: Immunohistochemical immunolabelling of cleaved caspase 3 in 4T1-Luc2 tumors treated or not by paclitaxel/navarixin.

Article Snippet: For ELISA assays, levels of different chemokines in cell supernatants were determined according to the manufacturer’s protocols using following kits: CXCL1 (Mouse CXCL1 Sandwich ELISA Kit, Proteintech) and CCL5 (Mouse CCL5 Sandwich ELISA Kit, Proteintech).

Techniques: CRISPR, In Vivo, Membrane, Ex Vivo, Immunohistochemical staining

Journal: bioRxiv

Article Title: Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

doi: 10.1101/2024.12.21.629876

Figure Lengend Snippet: A: SA-β-Gal reaction of 4T1-Luc2 cells treated by paclitaxel or not. B : Expression of CXCL1 and CXCL2 by human TNBC cells and their immune microenvironment (from scRNAseq of Broad Institute) C: CXCL1 and CXCL2 expression by human TNBC and associated prognosis according to the Bc-GenExMiner tool. D : Correlation between CXCL1 / CXCL2, anti-apoptotic and senescence markers using BC-GenExMiner tool.

Article Snippet: For ELISA assays, levels of different chemokines in cell supernatants were determined according to the manufacturer’s protocols using following kits: CXCL1 (Mouse CXCL1 Sandwich ELISA Kit, Proteintech) and CCL5 (Mouse CCL5 Sandwich ELISA Kit, Proteintech).

Techniques: Expressing